微動(dòng)態(tài)丨歐盟評(píng)估轉(zhuǎn)基因乳酸克魯維酵母菌株CIN生產(chǎn)的凝乳酶的安全性
(相關(guān)資料圖)
2022年8月11日,歐盟食品安全局就一種凝乳酶(chymosin)的安全性評(píng)價(jià)發(fā)布意見(jiàn)。據(jù)了解,這種食品酶是由轉(zhuǎn)基因乳酸克魯維酵母菌株CIN生產(chǎn)的,旨在用于奶酪生產(chǎn)和發(fā)酵乳制品生產(chǎn)的牛奶加工中。
經(jīng)過(guò)評(píng)估,專家小組認(rèn)為,在預(yù)期的使用條件下,不能排除飲食暴露引起過(guò)敏和誘發(fā)反應(yīng)的風(fēng)險(xiǎn),特別是對(duì)雪松花粉過(guò)敏源過(guò)敏的個(gè)體。根據(jù)所提供的數(shù)據(jù),評(píng)估小組得出結(jié)論,這種食品酶在預(yù)期使用條件下不會(huì)引起安全問(wèn)題。部分原文報(bào)道如下:
The food enzyme chymosin (EC 3.4.23.4) is produced with the genetically modified Kluyveromyces lactis strain CIN by DSM Food Specialties B.V. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and its recombinant DNA. It is intended to be used in milk processing for cheese production and for the production of fermented milk products. Dietary exposure was estimated to be up to 0.73 mg total organic solids (TOS)/kg body weight (bw) per day in European populations. Genotoxicity tests did not raise a safety concern. The systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 1,000 mg TOS/kg bw per day, the highest dose tested, which when compared with the estimated dietary exposure, results in a margin of exposure of at least 1,300. Similarity of the amino acid sequence of the food enzyme to those of known allergens was searched for and four matches were found. The Panel considered that under the intended conditions of use the risk of allergic sensitisation and elicitation reactions by dietary exposure, although unlikely, cannot be excluded, particularly for individuals sensitised to cedar pollen allergens. based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use.
標(biāo)簽: 酵母菌株 評(píng)估小組 安全問(wèn)題